PLPP4

Summary

PLPP4 (phospholipid phosphatase 4, HGNC:23531) is a protein-coding gene on chromosome 10q26.12, encoding Phospholipid phosphatase 4 (Q5VZY2). Magnesium-independent phospholipid phosphatase with broad substrate specificity.

Enables diacylglycerol diphosphate phosphatase activity; identical protein binding activity; and phosphatidate phosphatase activity. Involved in phospholipid dephosphorylation and regulation of calcium ion import. Predicted to be located in plasma membrane. Predicted to be active in membrane. Biomarker of breast cancer.

Source: NCBI Gene 196051 — RefSeq curated summary.

At a glance

• GWAS associations: 5
• Clinical variants (ClinVar): 33 total
• MANE Select transcript: NM_001030059

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:23531
Approved symbol	PLPP4
Name	phospholipid phosphatase 4
Location	10q26.12
Locus type	gene with protein product
Status	Approved
Aliases	DPPL2
Ensembl gene	ENSG00000203805
Ensembl biotype	protein_coding
Entrez	196051

Gene structure

Transcript identifiers

Ensembl transcripts: 3 — 2 protein_coding_CDS_not_defined, 1 protein_coding

ENST00000369073, ENST00000398250, ENST00000496437

RefSeq mRNA: 3 — MANE Select: NM_001030059 NM_001030059, NM_001318166, NM_001318167

CCDS: CCDS41573

Canonical transcript exons

ENST00000398250 — 7 exons

Exon	Start	End
ENSE00001448750	120575131	120575301
ENSE00001448751	120520971	120521095
ENSE00001448752	120518833	120518896
ENSE00001448753	120513911	120514001
ENSE00001448754	120503818	120503926
ENSE00001749139	120457227	120457361
ENSE00003500636	120589303	120592065

Expression profiles

Bgee: expression breadth ubiquitous, 175 present calls, max score 88.15.

FANTOM5 (CAGE): breadth broad, TPM avg 11.6473 / max 282.0314, expressed in 871 samples.

FANTOM5 promoters (7 alternative TSS)

Promoter ID	TPM avg	Samples expressed
107370	10.5487	851
107366	0.4046	154
107368	0.3005	91
107369	0.1579	72
107365	0.1138	56
107367	0.0803	54
107364	0.0415	11

Top tissues by expression

251 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
oocyte	CL:0000023	88.15	gold quality
secondary oocyte	CL:0000655	87.63	gold quality
hypothalamus	UBERON:0001898	86.28	gold quality
Ammon’s horn	UBERON:0001954	83.58	gold quality
substantia nigra	UBERON:0002038	83.39	gold quality
C1 segment of cervical spinal cord	UBERON:0006469	83.38	gold quality
amygdala	UBERON:0001876	83.04	gold quality
midbrain	UBERON:0001891	82.53	gold quality
spinal cord	UBERON:0002240	82.19	gold quality
pons	UBERON:0000988	81.28	gold quality
stromal cell of endometrium	CL:0002255	79.52	gold quality
putamen	UBERON:0001874	79.04	gold quality
anterior cingulate cortex	UBERON:0009835	78.73	gold quality
right hemisphere of cerebellum	UBERON:0014890	78.50	gold quality
cerebellar cortex	UBERON:0002129	78.45	gold quality
cerebellar hemisphere	UBERON:0002245	78.42	gold quality
caudate nucleus	UBERON:0001873	78.31	gold quality
cerebellum	UBERON:0002037	77.80	gold quality
kidney epithelium	UBERON:0004819	76.84	silver quality
temporal lobe	UBERON:0001871	76.78	gold quality
nucleus accumbens	UBERON:0001882	75.67	gold quality
prefrontal cortex	UBERON:0000451	75.48	gold quality
adult mammalian kidney	UBERON:0000082	75.30	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	75.14	gold quality
Brodmann (1909) area 9	UBERON:0013540	74.86	gold quality
right testis	UBERON:0004534	74.71	gold quality
right frontal lobe	UBERON:0002810	74.29	gold quality
corpus callosum	UBERON:0002336	74.21	gold quality
cerebral cortex	UBERON:0000956	74.14	gold quality
left testis	UBERON:0004533	74.12	gold quality

Single-cell (SCXA)

Detected in 3 experiment(s), a significant marker in 2.

Experiment	Marker?	Max mean expression
E-HCAD-25	yes	15.18
E-GEOD-93593	yes	4.97
E-ANND-3	no	2.28

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

18 targeting PLPP4, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-4482-3P	99.98	72.50	3147
HSA-MIR-570-3P	99.96	72.41	4910
HSA-MIR-205-3P	99.92	69.92	3165
HSA-MIR-4307	99.82	70.45	3374
HSA-MIR-4502	99.65	66.99	1021
HSA-MIR-298	99.63	67.56	1916
HSA-MIR-3942-3P	99.57	69.03	2854
HSA-MIR-4276	99.56	67.66	2514
HSA-MIR-3120-3P	99.54	70.28	2669
HSA-MIR-4687-3P	99.48	66.41	968
HSA-MIR-122B-3P	99.21	68.90	1333
HSA-MIR-21-3P	99.21	68.95	1312
HSA-MIR-6799-5P	99.14	65.72	2093
HSA-MIR-3152-3P	99.10	66.35	678
HSA-MIR-6895-3P	98.79	65.69	996
HSA-MIR-561-5P	98.25	68.13	1365
HSA-MIR-411-5P	97.11	66.82	601
HSA-MIR-11401	90.58	63.72	128

Literature-anchored findings (GeneRIF, showing 3)

• DPPL1 and DPPL2 represent a novel type of mammalian phosphatidate phosphatase. (PMID:17590538)
• Studied the clinical significance and biological roles of PLPP4 in lung carcinoma. (PMID:28851360)
• PPAPDC1A fusions and in-frame fusions containing a RhoGAP domain clearly define the aggressive subset (7.5%) of diffuse gastric cancer. (PMID:30361512)

Cross-species orthologs

12 orthologs

Organism	Symbol	Gene ID
danio_rerio	plpp4	ENSDARG00000098862
mus_musculus	Plpp4	ENSMUSG00000070366
rattus_norvegicus	Plpp4	ENSRNOG00000020424
drosophila_melanogaster	wun	FBGN0016078
drosophila_melanogaster	laza	FBGN0037163
drosophila_melanogaster	CG11438	FBGN0037164
drosophila_melanogaster	CG11437	FBGN0037165
drosophila_melanogaster	CG11426	FBGN0037166
drosophila_melanogaster	CG11425	FBGN0037167
drosophila_melanogaster	CG12746	FBGN0037341
drosophila_melanogaster	wun2	FBGN0041087
caenorhabditis_elegans		WBGENE00018756

Paralogs (9): PLPP1 (ENSG00000067113), PLPPR2 (ENSG00000105520), PLPPR5 (ENSG00000117598), PLPPR4 (ENSG00000117600), PLPPR3 (ENSG00000129951), PLPP2 (ENSG00000141934), PLPP5 (ENSG00000147535), PLPPR1 (ENSG00000148123), PLPP3 (ENSG00000162407)

Protein

Protein identifiers

Phospholipid phosphatase 4 — Q5VZY2 (reviewed: Q5VZY2)

Alternative names: Phosphatidic acid phosphatase type 2 domain-containing protein 1A

All UniProt accessions (1): Q5VZY2

UniProt curated annotations — full annotation on UniProt →

Function. Magnesium-independent phospholipid phosphatase with broad substrate specificity. Preferentially catalyzes the conversion of diacylglycerol pyrophosphate into phosphatidate but can also act on phosphatidate and lysophosphatidate. Phospholipid phosphatases are involved in both the synthesis of lipids and the degradation or generation of lipid-signaling molecules like diacylglycerol.

Subcellular location. Membrane.

Tissue specificity. Expressed mainly to the brain, kidney and testis, and to a lesser extent the bone marrow, thymus, prostate, liver and uterus.

Activity regulation. Magnesium-independent phospholipid phosphatase. Inhibited by N-ethylmaleimide.

Pathway. Lipid metabolism; phospholipid metabolism.

Similarity. Belongs to the PA-phosphatase related phosphoesterase family.

Isoforms (4)

UniProt ID	Names	Canonical?
Q5VZY2-1	1	yes
Q5VZY2-2	2
Q5VZY2-3	3
Q5VZY2-4	4

RefSeq proteins (3): NP_001025230, NP_001305095, NP_001305096 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000326	PAP2/HPO	Domain
IPR036938	PAP2/HPO_sf	Homologous_superfamily
IPR043216	PAP-like	Family

Pfam: PF01569

Enzyme classification (BRENDA):

• EC 3.1.3.4 — phosphatidate phosphatase (BRENDA: 31 organisms, 190 substrates, 196 inhibitors, 44 Km, 3 kcat entries)
• EC 3.1.3.81 — diacylglycerol diphosphate phosphatase (BRENDA: 0 organisms, 0 substrates, 0 inhibitors, 0 Km, 0 kcat entries)

Substrate kinetics (BRENDA)

10 substrates with measured Km, best-characterized 10. Km ranges are aggregated across organisms/conditions.

Substrate	Km (mM)	Measurements
PHOSPHATIDIC ACID	0.0054–1.2	17
LYSOPHOSPHATIDATE	0.046–0.179	3
PHOSPHATIDATE	0.284–0.369	3
SPHINGOSINE-1-PHOSPHATE	0.028–0.26	3
CERAMIDE-1-PHOSPHATE	0.022–0.052	2
DIACYLGLYCEROL DIPHOSPHATE	0.041–0.104	2
LYSOPHOSPHATIDIC ACID	0.295–0.58	2
1,2-DIACYL-SN-GLYCEROL-3-PHOSPHATE	0.5954	1
2-(4,4-DIFLUORO-5,7-DIMETHYL-4-BORA-3A,4A-DIAZA-	0.024	1
DIOCTANOYL PHOSPHATIDIC ACID	1.4	1

Catalyzed reactions (Rhea), 5 shown:

• a 1,2-diacyl-sn-glycero-3-phosphate + H2O = a 1,2-diacyl-sn-glycerol + phosphate (RHEA:27429)
• a 1,2-diacyl-sn-glycerol 3-diphosphate + H2O = a 1,2-diacyl-sn-glycero-3-phosphate + phosphate + H(+) (RHEA:27449)
• 1-(9Z-octadecenoyl)-sn-glycero-3-phosphate + H2O = 1-(9Z-octadecenoyl)-sn-glycerol + phosphate (RHEA:39835)
• 1,2-dioctanoyl-sn-glycero-3-diphosphate + H2O = 1,2-dioctanoyl-sn-glycero-3-phosphate + phosphate + H(+) (RHEA:42856)
• 1,2-dioctanoyl-sn-glycero-3-phosphate + H2O = 1,2-dioctanoyl-sn-glycerol + phosphate (RHEA:42860)

UniProt features (21 total): transmembrane region 6, region of interest 4, splice variant 4, mutagenesis site 3, active site 2, chain 1, site 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q5VZY2-F1	91.44	0.86

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Catalytic / active sites (3): 146 (proton donors); 202 (nucleophile); 206 (stabilizes the active site histidine for nucleophilic attack)

Mutagenesis-validated functional residues (3):

Position	Phenotype
109	loss of phosphatase activity; when associated with a-146 and with a-202.
146	loss of phosphatase activity; when associated with a-109 and with a-202.
202	loss of phosphatase activity; when associated with a-109 and with a-146.

Function

Pathways and Gene Ontology

Reactome pathways

1 pathways

ID	Pathway
R-HSA-2029485	Role of phospholipids in phagocytosis

MSigDB gene sets: 85 (showing top): GSE45365_CD8A_DC_VS_CD11B_DC_IFNAR_KO_MCMV_INFECTION_DN, GOBP_LIPID_MODIFICATION, GOBP_EMBRYO_DEVELOPMENT_ENDING_IN_BIRTH_OR_EGG_HATCHING, GOBP_PHOSPHOLIPID_METABOLIC_PROCESS, REACTOME_INNATE_IMMUNE_SYSTEM, GOBP_PHOSPHOLIPID_DEPHOSPHORYLATION, GOBP_ORGANOPHOSPHATE_METABOLIC_PROCESS, GOBP_VESICLE_MEDIATED_TRANSPORT, GOBP_MONOATOMIC_CATION_TRANSPORT, GOBP_REGULATION_OF_IMMUNE_RESPONSE, GOBP_IN_UTERO_EMBRYONIC_DEVELOPMENT, GOBP_CALCIUM_ION_IMPORT, GOBP_REGULATION_OF_CALCIUM_ION_IMPORT, GOBP_FC_RECEPTOR_SIGNALING_PATHWAY, GOBP_BLASTOCYST_DEVELOPMENT

GO Biological Process (6): blastocyst hatching (GO:0001835), phospholipid metabolic process (GO:0006644), Fc-gamma receptor signaling pathway involved in phagocytosis (GO:0038096), phospholipid dephosphorylation (GO:0046839), regulation of calcium ion import (GO:0090279), lipid metabolic process (GO:0006629)

GO Molecular Function (5): diacylglycerol diphosphate phosphatase activity (GO:0000810), phosphatidate phosphatase activity (GO:0008195), identical protein binding (GO:0042802), protein binding (GO:0005515), hydrolase activity (GO:0016787)

GO Cellular Component (2): plasma membrane (GO:0005886), membrane (GO:0016020)

Reactome top-level categories

Rollup of top-1 pathways:

Category	Pathways
Fcgamma receptor (FCGR) dependent phagocytosis	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
blastocyst development	1
hatching	1
lipid metabolic process	1
organophosphate metabolic process	1
Fc receptor mediated stimulatory signaling pathway	1
phagocytosis	1
Fc-gamma receptor signaling pathway	1
dephosphorylation	1
lipid modification	1
regulation of calcium ion transport	1
calcium ion import	1
primary metabolic process	1
pyrophosphatase activity	1
lipid phosphatase activity	1
protein binding	1
binding	1
catalytic activity	1
membrane	1
cell periphery	1
cellular anatomical structure	1

Protein interactions and networks

STRING

1032 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
PLPP4	PLPP7	Q8NBV4	541
PLPP4	PLPP6	Q8IY26	512
PLPP4	DGAT1	O75907	467
PLPP4	LPIN1	Q14693	464
PLPP4	PLPP2	O43688	461
PLPP4	TACC2	O95359	450
PLPP4	PLPP1	O14494	431
PLPP4	DGAT2	Q96PD7	430
PLPP4	PNPLA2	Q96AD5	420
PLPP4	DOLPP1	Q86YN1	408
PLPP4	PNPLA3	Q9NST1	399
PLPP4	AHCYL1	O43865	376
PLPP4	TACC1	O75410	375
PLPP4	CCDC24	Q8N4L8	364
PLPP4	AFF3	P51826	361

IntAct

107 interactions, top by confidence:

A	B	Type	Score
PLPP4	PLPP4	psi-mi:“MI:0915”(physical association)	0.670
PLPP4	SAR1A	psi-mi:“MI:0915”(physical association)	0.560
PLPP4	PAGE1	psi-mi:“MI:0915”(physical association)	0.560
PLPP4	CPLX4	psi-mi:“MI:0915”(physical association)	0.560
PLPP4		psi-mi:“MI:0915”(physical association)	0.560
SGPL1	PLPP4	psi-mi:“MI:0915”(physical association)	0.560
PLPP4	ERGIC3	psi-mi:“MI:0915”(physical association)	0.560
STX2	PLPP4	psi-mi:“MI:0915”(physical association)	0.560
STX1A	PLPP4	psi-mi:“MI:0915”(physical association)	0.560
BIK	PLPP4	psi-mi:“MI:0915”(physical association)	0.560
PLPP4	ANKRD46	psi-mi:“MI:0915”(physical association)	0.560
PLPP4	LRRC59	psi-mi:“MI:0915”(physical association)	0.560
FRMD3	PLPP4	psi-mi:“MI:0915”(physical association)	0.560
SLC35A1	PLPP4	psi-mi:“MI:0915”(physical association)	0.560
PLPP4	CREB3L1	psi-mi:“MI:0915”(physical association)	0.560
CD74	PLPP4	psi-mi:“MI:0915”(physical association)	0.560
PLPP4	BCL2L13	psi-mi:“MI:0915”(physical association)	0.560
ARL13B	PLPP4	psi-mi:“MI:0915”(physical association)	0.560
PLPP4	TMEM139	psi-mi:“MI:0915”(physical association)	0.560
	PLPP4	psi-mi:“MI:0915”(physical association)	0.560
GJB5	PLPP4	psi-mi:“MI:0915”(physical association)	0.560
GJA1	PLPP4	psi-mi:“MI:0915”(physical association)	0.560
PAGE1	PLPP4	psi-mi:“MI:0915”(physical association)	0.560
FAM209A	PLPP4	psi-mi:“MI:0915”(physical association)	0.560
UPK1B	PLPP4	psi-mi:“MI:0915”(physical association)	0.560

BioGRID (52): PPAPDC1A (Two-hybrid), PPAPDC1A (Two-hybrid), PPAPDC1A (Two-hybrid), PPAPDC1A (Two-hybrid), PPAPDC1A (Two-hybrid), PPAPDC1A (Two-hybrid), PPAPDC1A (Two-hybrid), PPAPDC1A (Two-hybrid), PPAPDC1A (Two-hybrid), PPAPDC1A (Two-hybrid), PPAPDC1A (Two-hybrid), PPAPDC1A (Two-hybrid), PPAPDC1A (Two-hybrid), PPAPDC1A (Two-hybrid), PPAPDC1A (Two-hybrid)

ESM2 similar proteins: A6H7A0, A6NI61, A6QQ59, B0BMW8, B0CM95, B0KWE9, B1MTH4, B2KI79, F1LTR1, O14494, O43688, O88956, P0CK96, P57791, P60588, P86229, Q0VBU9, Q13888, Q1JQE6, Q2HJ61, Q3ZCD7, Q4L208, Q4R8V4, Q5R589, Q5R8Y5, Q5RL79, Q5VZY2, Q5ZJ75, Q5ZJH8, Q64232, Q6PIU2, Q86YN1, Q8C811, Q8K593, Q8N6L1, Q8NFT2, Q8R4D1, Q8VDI9, Q91ZH7, Q9CY27

Diamond homologs: O08564, O14494, O14495, O43688, O88956, P60588, P97544, Q04396, Q0VBU9, Q0WNG6, Q10022, Q2HJ61, Q3SZE3, Q3UMZ3, Q5VZY2, Q61469, Q6GQ62, Q6IQH6, Q86AF0, Q8K593, Q8LFD1, Q8NEB5, Q99JY8, Q9DAX2, Q9V576, Q9XI60, B0CM95, B0KWE9, B1MTH4, Q86YN1, Q9ZU49, B2KI79, Q05521, Q54PR7, Q9UUA6, Q6GM05, Q8BJ52, Q8MXL9, Q6WAY2, Q8TBJ4

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

33 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	29
Likely benign	1
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

2125 predictions. Top by Δscore:

Variant	Effect	Δscore
10:120457360:GT:G	donor_gain	1.0000
10:120457362:G:GG	donor_gain	1.0000
10:120503810:T:G	acceptor_gain	1.0000
10:120503816:A:AG	acceptor_gain	1.0000
10:120503817:G:GA	acceptor_gain	1.0000
10:120503817:GT:G	acceptor_gain	1.0000
10:120503923:GTTT:G	donor_gain	1.0000
10:120503924:TTT:T	donor_gain	1.0000
10:120503924:TTTG:T	donor_loss	1.0000
10:120503925:TT:T	donor_gain	1.0000
10:120503926:TGTAA:T	donor_loss	1.0000
10:120503927:G:GG	donor_gain	1.0000
10:120503928:TAA:T	donor_loss	1.0000
10:120503929:AAGTA:A	donor_loss	1.0000
10:120503930:AGTAC:A	donor_loss	1.0000
10:120513989:G:GT	donor_gain	1.0000
10:120521096:G:GG	donor_gain	1.0000
10:120575125:TGGCA:T	acceptor_loss	1.0000
10:120575126:GGCA:G	acceptor_loss	1.0000
10:120575127:GCA:G	acceptor_loss	1.0000
10:120575128:CAG:C	acceptor_loss	1.0000
10:120575129:A:AG	acceptor_gain	1.0000
10:120575129:AGTT:A	acceptor_gain	1.0000
10:120575130:G:GG	acceptor_gain	1.0000
10:120575130:GTT:G	acceptor_gain	1.0000
10:120575130:GTTG:G	acceptor_gain	1.0000
10:120575297:GCAAG:G	donor_gain	1.0000
10:120575300:AGGT:A	donor_loss	1.0000
10:120575302:G:GG	donor_gain	1.0000
10:120575302:GTGA:G	donor_loss	1.0000

AlphaMissense

1765 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
10:120520999:T:C	F117L	0.999
10:120521001:T:A	F117L	0.999
10:120521001:T:G	F117L	0.999
10:120518892:G:A	G106R	0.998
10:120518892:G:C	G106R	0.998
10:120518893:G:A	G106E	0.998
10:120520996:T:A	C116S	0.998
10:120520996:T:C	C116R	0.998
10:120520997:G:C	C116S	0.998
10:120521062:G:C	G138R	0.998
10:120521066:G:C	R139P	0.998
10:120521074:T:C	F142L	0.998
10:120521076:C:A	F142L	0.998
10:120521076:C:G	F142L	0.998
10:120589326:G:C	G214R	0.998
10:120589327:G:A	G214D	0.998
10:120503840:T:C	F27L	0.997
10:120503842:C:A	F27L	0.997
10:120503842:C:G	F27L	0.997
10:120513930:C:A	P62H	0.997
10:120513930:C:G	P62R	0.997
10:120518860:G:A	G95E	0.997
10:120518893:G:T	G106V	0.997
10:120520979:C:A	P110H	0.997
10:120520984:T:C	F112L	0.997
10:120520986:C:A	F112L	0.997
10:120520986:C:G	F112L	0.997
10:120520994:G:C	R115P	0.997
10:120520998:C:G	C116W	0.997
10:120521032:T:A	C128S	0.997

dbSNP variants (sampled 300 via entrez): RS1000017278 (10:120540140 CA>C), RS1000034138 (10:120476224 G>A,T), RS1000034605 (10:120503353 C>G), RS1000046609 (10:120545922 A>G), RS1000070581 (10:120533481 C>G), RS1000089551 (10:120487543 T>A,C), RS1000128427 (10:120579885 A>G), RS1000136174 (10:120496555 T>C,G), RS1000141919 (10:120534672 A>G), RS1000170474 (10:120569413 G>A), RS1000182359 (10:120557343 G>A), RS1000225214 (10:120478848 A>C), RS1000279045 (10:120575221 T>C), RS1000301313 (10:120521040 T>C), RS1000301898 (10:120562893 A>G)

Disease associations

OMIM: gene `` | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

5 associations (top):

Study	Trait	p-value
GCST001915_25	Alzheimer’s disease (cognitive decline)	6.000000e-07
GCST003475_3	Beard thickness	1.000000e-06
GCST012292_7	Schizophrenia, bipolar disorder or recurrent major depressive disorder x sex interaction	6.000000e-06
GCST012298_6	Schizophrenia, bipolar disorder or major depressive disorder x sex interaction	6.000000e-07
GCST012301_4	Schizophrenia, bipolar disorder or major depressive disorder x sex interaction	5.000000e-06

EFO canonical traits (2, from GWAS)

EFO ID	Trait name
EFO:0004952	disease recurrence
EFO:0008343	sex interaction measurement

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

34 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects cotreatment, decreases expression, affects expression, increases methylation	6
entinostat	decreases expression, affects cotreatment	2
Nickel	decreases expression	2
methylmercuric chloride	decreases expression	1
bisphenol A	affects methylation	1
trichostatin A	decreases expression	1
sodium arsenite	decreases expression	1
potassium chromate(VI)	decreases expression	1
nickel sulfate	decreases expression	1
CGP 52608	affects binding, increases reaction	1
monomethylarsonous acid	decreases expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, decreases expression	1
dimethylarsinous acid	decreases expression	1
dorsomorphin	affects cotreatment, decreases expression	1
bisphenol S	increases expression	1
(+)-JQ1 compound	decreases expression	1
Temozolomide	decreases expression	1
Microplastics	increases abundance, increases expression	1
Air Pollutants	decreases expression, increases abundance	1
Benzo(a)pyrene	affects methylation	1
Cadmium	increases expression	1
Calcitriol	decreases expression	1
Dichlorodiphenyl Dichloroethylene	decreases expression	1
Dexamethasone	decreases expression	1
Doxorubicin	decreases expression	1
Methyl Methanesulfonate	increases expression	1
Polyethylene Terephthalates	increases expression, increases abundance	1
Testosterone	decreases expression	1
Tretinoin	increases expression	1
Triclosan	increases expression	1

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.